131 related articles for article (PubMed ID: 35891756)
1. Evaluation of the Role of the KRAS Gene Polymorphism LCS6 (rs61764370) in Iraqi Women with Ovarian Cancer.
Ghazi Jumaa M
Arch Razi Inst; 2022 Feb; 77(1):205-211. PubMed ID: 35891756
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.
Uvirova M; Simova J; Kubova B; Dvorackova N; Tomaskova H; Sedivcova M; Dite P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):466-71. PubMed ID: 26077004
[TBL] [Abstract][Full Text] [Related]
3. Association between rs61764370, rs9266, and rs140080026 polymorphisms of the KRAS gene and breast cancer risk in a Mexican population.
Gallegos-Arreola MP; García Verdín PM; Magaña-Torres MT; Figuera LE; Zúñiga-González GM; Rosales-Reynoso MA; Gómez-Meda BC; Puebla-Pérez AM
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(21):6454-6464. PubMed ID: 34787849
[TBL] [Abstract][Full Text] [Related]
4. The let-7 microRNA binding site variant in KRAS as a predictive biomarker for head and neck cancer patients with lymph node metastasis.
Ulusan M; Sen S; Yilmazer R; Dalay N; Demokan S
Pathol Res Pract; 2022 Nov; 239():154147. PubMed ID: 36228348
[TBL] [Abstract][Full Text] [Related]
5. A let-7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population.
Kazmi HR; Chandra A; Kumar S; Satyam LK; Gupta A; Nigam J; Srivastava M; Mittal B
J Cancer Res Clin Oncol; 2016 Dec; 142(12):2577-2583. PubMed ID: 27620744
[TBL] [Abstract][Full Text] [Related]
6. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.
Sebio A; Paré L; Páez D; Salazar J; González A; Sala N; del Río E; Martín-Richard M; Tobeña M; Barnadas A; Baiget M
Pharmacogenet Genomics; 2013 Mar; 23(3):142-7. PubMed ID: 23324806
[TBL] [Abstract][Full Text] [Related]
7. Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).
Sha D; Lee AM; Shi Q; Alberts SR; Sargent DJ; Sinicrope FA; Diasio RB
Clin Cancer Res; 2014 Jun; 20(12):3319-27. PubMed ID: 24727325
[TBL] [Abstract][Full Text] [Related]
8. The relationship between
Çintesun FNİ; Kerimoğlu ÖS; Çintesun E; Nergiz S; Acar H; Çelik Ç
J Obstet Gynaecol; 2020 Oct; 40(7):988-993. PubMed ID: 31790621
[TBL] [Abstract][Full Text] [Related]
9. No evidence for genetic association with the let-7 microRNA-binding site or other common KRAS variants in risk of endometriosis.
Luong HT; Nyholt DR; Painter JN; Chapman B; Kennedy S; Treloar SA; Zondervan KT; Montgomery GW
Hum Reprod; 2012 Dec; 27(12):3616-21. PubMed ID: 23010532
[TBL] [Abstract][Full Text] [Related]
10. A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy.
Zhang W; Winder T; Ning Y; Pohl A; Yang D; Kahn M; Lurje G; LaBonte MJ; Wilson PM; Gordon MA; Hu-Lieskovan S; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
Ann Oncol; 2011 Jan; 22(1):104-109. PubMed ID: 20603437
[TBL] [Abstract][Full Text] [Related]
11. The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.
Pharoah PD; Palmieri RT; Ramus SJ; Gayther SA; Andrulis IL; Anton-Culver H; Antonenkova N; Antoniou AC; Goldgar D; ; Beattie MS; Beckmann MW; Birrer MJ; Bogdanova N; Bolton KL; Brewster W; Brooks-Wilson A; Brown R; Butzow R; Caldes T; Caligo MA; Campbell I; Chang-Claude J; Chen YA; Cook LS; Couch FJ; Cramer DW; Cunningham JM; Despierre E; Doherty JA; Dörk T; Dürst M; Eccles DM; Ekici AB; Easton D; ; Fasching PA; de Fazio A; Fenstermacher DA; Flanagan JM; Fridley BL; Friedman E; Gao B; Sinilnikova O; ; Gentry-Maharaj A; Godwin AK; Goode EL; Goodman MT; Gross J; Hansen TV; Harnett P; Rookus M; ; Heikkinen T; Hein R; Høgdall C; Høgdall E; Iversen ES; Jakubowska A; Johnatty SE; Karlan BY; Kauff ND; Kaye SB; Chenevix-Trench G; ; Kelemen LE; Kiemeney LA; Kjaer SK; Lambrechts D; Lapolla JP; Lázaro C; Le ND; Leminen A; Leunen K; Levine DA; Lu Y; Lundvall L; Macgregor S; Marees T; Massuger LF; McLaughlin JR; Menon U; Montagna M; Moysich KB; Narod SA; Nathanson KL; Nedergaard L; Ness RB; Nevanlinna H; Nickels S; Osorio A; Paul J; Pearce CL; Phelan CM; Pike MC; Radice P; Rossing MA; Schildkraut JM; Sellers TA; Singer CF; Song H; Stram DO; Sutphen R; Lindblom A; ; Terry KL; Tsai YY; van Altena AM; Vergote I; Vierkant RA; Vitonis AF; Walsh C; Wang-Gohrke S; Wappenschmidt B; Wu AH; Ziogas A; Berchuck A; Risch HA;
Clin Cancer Res; 2011 Jun; 17(11):3742-50. PubMed ID: 21385923
[TBL] [Abstract][Full Text] [Related]
12. The rs61764370 Functional Variant in the KRAS Oncogene is Associated with Chronic Myeloid Leukemia Risk in Women.
Gutiérrez-Malacatt H; Ayala-Sanchez M; Aquino-Ortega X; Dominguez-Rodriguez J; Martinez-Tovar A; Olarte-Carrillo I; Martinez-Hernandez A; C CC; Orozco L; Cordova EJ
Asian Pac J Cancer Prev; 2016; 17(4):2265-70. PubMed ID: 27221928
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.
Hollestelle A; Pelletier C; Hooning M; Crepin E; Schutte M; Look M; Collee JM; Nieuwlaat A; Dorssers LC; Seynaeve C; Aulchenko YS; Martens JW; van den Ouweland AM; Weidhaas JB
Breast Cancer Res Treat; 2011 Jul; 128(1):79-84. PubMed ID: 20676756
[TBL] [Abstract][Full Text] [Related]
14. Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.
Kjersem JB; Ikdahl T; Guren T; Skovlund E; Sorbye H; Hamfjord J; Pfeiffer P; Glimelius B; Kersten C; Solvang H; Tveit KM; Kure EH
BMC Cancer; 2012 Nov; 12():534. PubMed ID: 23167843
[TBL] [Abstract][Full Text] [Related]
15. rs61764370 polymorphism of Kras and risk of cancer in Caucasian population: A meta-analysis.
Zhang SY; Shi J
J Cancer Res Ther; 2016; 12(2):699-704. PubMed ID: 27461636
[TBL] [Abstract][Full Text] [Related]
16. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.
Saridaki Z; Weidhaas JB; Lenz HJ; Laurent-Puig P; Jacobs B; De Schutter J; De Roock W; Salzman DW; Zhang W; Yang D; Pilati C; Bouché O; Piessevaux H; Tejpar S
Clin Cancer Res; 2014 Sep; 20(17):4499-4510. PubMed ID: 25183481
[TBL] [Abstract][Full Text] [Related]
17. Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis.
Langevin SM; Christensen BC
Cancer Med; 2014 Oct; 3(5):1385-95. PubMed ID: 24890702
[TBL] [Abstract][Full Text] [Related]
18. A single nucleotide polymorphism in the 3'-untranslated region of the KRAS gene disrupts the interaction with let-7a and enhances the metastatic potential of osteosarcoma cells.
Zhang S; Hou C; Li G; Zhong Y; Zhang J; Guo X; Li B; Bi Z; Shao M
Int J Mol Med; 2016 Sep; 38(3):919-26. PubMed ID: 27430246
[TBL] [Abstract][Full Text] [Related]
19. Association of Rs61764370 polymorphism within let-7 microRNA-binding site with lung cancer in Iranian population.
Farokhzad N; Hosseini SM; Edalat H; Sadeghi M
Afr Health Sci; 2020 Sep; 20(3):1299-1303. PubMed ID: 33402978
[TBL] [Abstract][Full Text] [Related]
20. KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer.
Caiola E; Rulli E; Fruscio R; Buda A; Broggini M; Marabese M
Am J Cancer Res; 2012; 2(3):298-308. PubMed ID: 22679560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
